Skip to main content
Erschienen in: Clinical and Experimental Medicine 4/2010

01.12.2010 | Original Article

Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma

verfasst von: Toni Valković, Antica Duletić-Načinović, Sanja Štifter, Milena Hasan, Ita Hadžisejdić, David Zombori, Blaženka Grahovac, Nives Jonjić

Erschienen in: Clinical and Experimental Medicine | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Non-Hodgkin lymphoma (NHL) is one of the most common malignancies whose incidence increases, and the treatment results are not satisfactory. The aim of this study was to determine the capacity of NHL to produce MCP-1, chemokine that induces chemotaxis of macrophages and lymphoid cells. The mRNA expression and protein MCP-1 expression were determined in the samples of 20 patients with NHL and 8 reactive tonsils. MCP-1 mRNA was detected in 8/8 tonsils and in 19/20 patients with NHL by real-time PCR analysis. In addition, the amount of detected MCP-1 cDNA was significantly higher in patients with limited stage, good IPI, normal level of fibrinogen and LDH. Finally, in patients with aggressive NHL, the level of MCP-1 cDNA was higher than in indolent tumours. Immunohistochemical analysis revealed that majority of stromal elements such as macrophages, endothelial and smooth muscle cells in reactive as well as in neoplastic lymphoid tissue showed strong cytoplasmic MCP-1 expression. Moderate cytoplasmic MCP-1 expression was also observed in reactive lymphocytes, while tumour cells of indolent NHL were mostly pale in comparison with aggressive lymphomas which predominantly demonstrated intense MCP-1 staining. These intriguing preliminary results emphasize the need for further investigations that must be conducted on the representative sample with concordant measurement of serum MCP-1 level.
Literatur
1.
2.
Zurück zum Zitat McLaughlin P (2002) Progress and promise in the treatment of indolent lymphomas. Oncologist 7:217–225CrossRefPubMed McLaughlin P (2002) Progress and promise in the treatment of indolent lymphomas. Oncologist 7:217–225CrossRefPubMed
3.
Zurück zum Zitat Grillo-Lopez AJ (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2:485–493CrossRefPubMed Grillo-Lopez AJ (2002) Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma. Expert Rev Anticancer Ther 2:485–493CrossRefPubMed
4.
Zurück zum Zitat Coiffier B (2003) Immunochemotherapy: the new standard in aggressive non-Hodgkin’s lymphoma in the elderly. Semin Oncol 30(Suppl 2):21–27CrossRefPubMed Coiffier B (2003) Immunochemotherapy: the new standard in aggressive non-Hodgkin’s lymphoma in the elderly. Semin Oncol 30(Suppl 2):21–27CrossRefPubMed
6.
Zurück zum Zitat Preti HA, Cabanillas F, Talpaz M, Tucker SL, Segmour JF, Kurzrock R (1997) Prognostic value of serum IL-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186–194PubMed Preti HA, Cabanillas F, Talpaz M, Tucker SL, Segmour JF, Kurzrock R (1997) Prognostic value of serum IL-6 in diffuse large-cell lymphoma. Ann Intern Med 127:186–194PubMed
7.
Zurück zum Zitat Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13:575–582PubMed Seymour JF, Talpaz M, Cabanillas F, Wetzler M, Kurzrock R (1995) Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. J Clin Oncol 13:575–582PubMed
8.
Zurück zum Zitat Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R (1998) High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 30:563–571PubMed Fayad L, Cabanillas F, Talpaz M, McLaughlin P, Kurzrock R (1998) High serum interleukin-6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 30:563–571PubMed
10.
Zurück zum Zitat Laurence ADJ (2005) Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol 132:255–267CrossRef Laurence ADJ (2005) Location, movement and survival: the role of chemokines in haematopoiesis and malignancy. Br J Haematol 132:255–267CrossRef
11.
Zurück zum Zitat Myers SJ, Wong LM, Charo IF (1996) Signal transduction and ligand specificity of the human monocyte chemotactic protein-1 receptor in transfected embryonic kidney cells. J Biol Chem 270:5786–5792 Myers SJ, Wong LM, Charo IF (1996) Signal transduction and ligand specificity of the human monocyte chemotactic protein-1 receptor in transfected embryonic kidney cells. J Biol Chem 270:5786–5792
12.
Zurück zum Zitat Bernardini G, Ribatti D, Spinetti G, Morbidelli L, Ziche M, Santoni A, Capogrossi MC, Napolitano M (2002) Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273:83–101CrossRef Bernardini G, Ribatti D, Spinetti G, Morbidelli L, Ziche M, Santoni A, Capogrossi MC, Napolitano M (2002) Analysis of the role of chemokines in angiogenesis. J Immunol Methods 273:83–101CrossRef
13.
Zurück zum Zitat Vanderkerken K, Van de Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B (2002) Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T33MM multiple myeloma cells. Clin Exp Metastasis 19:87–90CrossRefPubMed Vanderkerken K, Van de Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, Van Camp B (2002) Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5T33MM multiple myeloma cells. Clin Exp Metastasis 19:87–90CrossRefPubMed
14.
Zurück zum Zitat Johrer K, Janke K, Krugmann J, Fiegl M, Griel R (2004) Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 15:1901–1910CrossRef Johrer K, Janke K, Krugmann J, Fiegl M, Griel R (2004) Transendothelial migration of myeloma cells is increased by tumor necrosis factor (TNF)-alpha via TNF receptor 2 and autocrine up-regulation of MCP-1. Clin Cancer Res 15:1901–1910CrossRef
15.
Zurück zum Zitat Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP (1998) The monocyte chemotactic protein-1 (MCP-1) and interleukine 8 (IL-8) in Hodgkin’s disease and in solid tumors. Mol Pathol 51:273–276CrossRefPubMed Luciani MG, Stoppacciaro A, Peri G, Mantovani A, Ruco LP (1998) The monocyte chemotactic protein-1 (MCP-1) and interleukine 8 (IL-8) in Hodgkin’s disease and in solid tumors. Mol Pathol 51:273–276CrossRefPubMed
16.
Zurück zum Zitat Chan JK (2001) The new world health organization classification of lymphomas: the past, the present and the future. Hematol Oncol 19:129–150CrossRefPubMed Chan JK (2001) The new world health organization classification of lymphomas: the past, the present and the future. Hematol Oncol 19:129–150CrossRefPubMed
17.
Zurück zum Zitat Carbone PP, Kaplan HS, Mushoff K, Smithers DW, Tubiana M (1971) Report of the committee in Hodgkin’s disease staging classification. Cancer Res 31:1860–1861PubMed Carbone PP, Kaplan HS, Mushoff K, Smithers DW, Tubiana M (1971) Report of the committee in Hodgkin’s disease staging classification. Cancer Res 31:1860–1861PubMed
18.
Zurück zum Zitat Hermans J, Krol AD, van Groningen K, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans PW (1995) International prognostic index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 86:1460–1463PubMed Hermans J, Krol AD, van Groningen K, Kluin-Nelemans JC, Kramer MH, Noordijk EM, Ong F, Wijermans PW (1995) International prognostic index for aggressive non-Hodgkin’s lymphoma is valid for all malignancy grades. Blood 86:1460–1463PubMed
19.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655CrossRefPubMed Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655CrossRefPubMed
20.
Zurück zum Zitat Duletic-Nacinovic A, Sever-Prebilic M, Stifter S, Jonjic N, Hasan M, Labar B (2006) Interleukin-6 in patients with aggressive and indolent non-Hodgkin’s lymphoma: a predictor of prognosis. Clin Oncol 18:367–368CrossRef Duletic-Nacinovic A, Sever-Prebilic M, Stifter S, Jonjic N, Hasan M, Labar B (2006) Interleukin-6 in patients with aggressive and indolent non-Hodgkin’s lymphoma: a predictor of prognosis. Clin Oncol 18:367–368CrossRef
21.
Zurück zum Zitat Serebriakov NB, Novik AA, Shamanskü SV (1998) Diagnostic and prognostic value of interleukin-6 in malignant non Hodgkin’s lymphomas. Vestn Ross Akad Med Nauk 10:32–36PubMed Serebriakov NB, Novik AA, Shamanskü SV (1998) Diagnostic and prognostic value of interleukin-6 in malignant non Hodgkin’s lymphomas. Vestn Ross Akad Med Nauk 10:32–36PubMed
22.
Zurück zum Zitat Yee CY, Biondi A, Wang XH, Iscove NN, deSousa J, Aarden LA, Wong GG, Clark SC, Messner HA (1989) A possible autocrine role of interleukin-6 in two lymphoma cell lines. Blood 74:798–804PubMed Yee CY, Biondi A, Wang XH, Iscove NN, deSousa J, Aarden LA, Wong GG, Clark SC, Messner HA (1989) A possible autocrine role of interleukin-6 in two lymphoma cell lines. Blood 74:798–804PubMed
23.
Zurück zum Zitat Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34–40PubMed Salcedo R, Ponce ML, Young HA, Wasserman K, Ward JM, Kleinman HK, Oppenheim JJ, Murphy WJ (2000) Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 96:34–40PubMed
24.
Zurück zum Zitat Hong KH, Jewon R, Han KH (2005) Monocyte chemoattractant protein-1 induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105:1405–1407CrossRefPubMed Hong KH, Jewon R, Han KH (2005) Monocyte chemoattractant protein-1 induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105:1405–1407CrossRefPubMed
25.
Zurück zum Zitat Kim MY, Byeon CW, Hong KH, Han KH, Jeong S (2005) Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 579:1597–1601CrossRefPubMed Kim MY, Byeon CW, Hong KH, Han KH, Jeong S (2005) Inhibition of the angiogenesis by the MCP-1 (monocyte chemoattractant protein-1) binding peptide. FEBS Lett 579:1597–1601CrossRefPubMed
26.
Zurück zum Zitat Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Br J Cancer 79:965–970CrossRefPubMed Vacca A, Ribatti D, Ruco L, Giacchetta F, Nico B, Quondamatteo F, Ria R, Iurlaro M, Dammacco F (1999) Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin’s lymphomas. Br J Cancer 79:965–970CrossRefPubMed
27.
Zurück zum Zitat Tedla N, Palladinetti P, Wakefield D, Lloyd A (1999) Abundant expression of chemokines in malignant and infective human lymphadenopathies. Cytokine 11:531–540CrossRefPubMed Tedla N, Palladinetti P, Wakefield D, Lloyd A (1999) Abundant expression of chemokines in malignant and infective human lymphadenopathies. Cytokine 11:531–540CrossRefPubMed
28.
Zurück zum Zitat Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, de Leval L, Schultze J, Freedman AS (2001) MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 115:554–562CrossRefPubMed Husson H, Carideo EG, Cardoso AA, Lugli SM, Neuberg D, Munoz O, de Leval L, Schultze J, Freedman AS (2001) MCP-1 modulates chemotaxis by follicular lymphoma cells. Br J Haematol 115:554–562CrossRefPubMed
29.
Zurück zum Zitat Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R, Adami F, Agostini C, Semenzato G (2004) Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 104:502–508CrossRefPubMed Trentin L, Cabrelle A, Facco M, Carollo D, Miorin M, Tosoni A, Pizzo P, Binotto G, Nicolardi L, Zambello R, Adami F, Agostini C, Semenzato G (2004) Homeostatic chemokines drive migration of malignant B cells in patients with non-Hodgkin lymphomas. Blood 104:502–508CrossRefPubMed
Metadaten
Titel
Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma
verfasst von
Toni Valković
Antica Duletić-Načinović
Sanja Štifter
Milena Hasan
Ita Hadžisejdić
David Zombori
Blaženka Grahovac
Nives Jonjić
Publikationsdatum
01.12.2010
Verlag
Springer Milan
Erschienen in
Clinical and Experimental Medicine / Ausgabe 4/2010
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-010-0093-6

Weitere Artikel der Ausgabe 4/2010

Clinical and Experimental Medicine 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.